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To the Editor,
We carefully read the recently published research letter “Is asthma protective of COVID-19?” by Carli et 
al.1 with great interest. Important topics for asthma patients during the coronavirus disease 2019 (COVID-
19) pandemic were discussed, including that until recently there was limited evidence that patients with 
chronic respiratory disorders are at lower risk of being infected with Severe Acute Respiratory Syndrome 
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Only taking into account previous reports from China and Italy, where asthma was underrepresented in 
COVID-19 patients, the authors acknowledge the heterogeneous condition that is asthma, suggesting that 
T2-immunity, interferon-mediated immune responses and increased number of eosinophils in the airways 
could have a protective effect against COVID-19 severity.1
The epidemiology of COVID-19 is changing rapidly with new data. More recent reports from the United 
States of America and from several European countries, in particular the United Kingdom (UK), states a 
higher asthma prevalence in patients with COVID-19, suggesting that asthma is more common in COVID-
19 patients than it was previously reported in Asia and in the first European surveys.2 Data from the UK 
Biobank, a large prospective case-control study, found an asthma prevalence of 17,9% in 605 COVID-19 
hospitalized patients, mostly of them adults, surpassing the prevalence of asthma in the general 
population.3
In the OpenSAFELY Collaborative Study (UK), a significant increased risk of severe COVID-19 disease and 
mortality rate was found in patients with asthma, particularly in patients with recent oral corticosteroids 
(OCS) use.4 These findings indicate an increased asthma severity and/or poor control, and in accordance 
with data from previous coronavirus outbreaks, that the use of systemic corticosteroids can be associated 
with a higher viral load.5
We agree with Carli et al1 that further studies focused on asthma and its different phenotypes are needed 
to improve our understanding of the association between asthma and COVID-19 severity.6 Factors as co-
viral infections, that were quite low in the first Chinese and Italian reports, or different exposures to 
allergens or irritants, as tobacco smoke, can justify some of the differences found in asthma prevalence 
between the available case-series. 
Based on current recommendations, it is crucial that patients with asthma do not stop their controller 
medication, which may lead to a higher risk of asthma exacerbations, emergency room visits, 
hospitalization, and increased use of OCS.   
In conclusion, according to the available data, patients with asthma must still be included in the high-risk 
COVID-19 groups and further research is warranted to improve our understanding of the relationship 
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